These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21306895)

  • 1. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.
    Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Kim HJ; Kwak WY; Min JP; Lee JY; Yoon TH; Kim HD; Shin CY; Kim MK; Choi SH; Kim HS; Yang EK; Cheong YH; Chae YN; Park KJ; Jang JM; Choi SJ; Son MH; Kim SH; Yoo M; Lee BJ
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3809-12. PubMed ID: 21570283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
    Wang L; Zhang B; Ji J; Li B; Yan J; Zhang W; Wu Y; Wang X
    Eur J Med Chem; 2009 Aug; 44(8):3318-22. PubMed ID: 19375196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
    Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL
    J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors.
    Zhu Y; Xia S; Zhu M; Yi W; Cheng J; Song G; Li Z; Lu P
    Eur J Med Chem; 2010 Nov; 45(11):4953-62. PubMed ID: 20800322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
    Namoto K; Sirockin F; Ostermann N; Gessier F; Flohr S; Sedrani R; Gerhartz B; Trappe J; Hassiepen U; Duttaroy A; Ferreira S; Sutton JM; Clark DE; Fenton G; Beswick M; Baeschlin DK
    Bioorg Med Chem Lett; 2014 Feb; 24(3):731-6. PubMed ID: 24439847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.
    Sutton JM; Clark DE; Dunsdon SJ; Fenton G; Fillmore A; Harris NV; Higgs C; Hurley CA; Krintel SL; MacKenzie RE; Duttaroy A; Gangl E; Maniara W; Sedrani R; Namoto K; Ostermann N; Gerhartz B; Sirockin F; Trappe J; Hassiepen U; Baeschlin DK
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1464-8. PubMed ID: 22177783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead optimization of [(S)-gamma-(arylamino)prolyl]thiazolidine focused on gamma-substituent: Indoline compounds as potent DPP-IV inhibitors.
    Sakashita H; Akahoshi F; Yoshida T; Kitajima H; Hayashi Y; Ishii S; Takashina Y; Tsutsumiuchi R; Ono S
    Bioorg Med Chem; 2007 Jan; 15(2):641-55. PubMed ID: 17113301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.
    Ahn JH; Shin MS; Jun MA; Jung SH; Kang SK; Kim KR; Rhee SD; Kang NS; Kim SY; Sohn SK; Kim SG; Jin MS; Lee JO; Cheon HG; Kim SS
    Bioorg Med Chem Lett; 2007 May; 17(9):2622-8. PubMed ID: 17331715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.
    Lam B; Zhang Z; Stafford JA; Skene RJ; Shi L; Gwaltney SL
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6628-31. PubMed ID: 23025999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
    Al-masri IM; Mohammad MK; Tahaa MO
    J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1061-6. PubMed ID: 19640223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
    Xie H; Zeng L; Zeng S; Lu X; Zhao X; Zhang G; Tu Z; Xu H; Yang L; Zhang X; Wang S; Hu W
    Eur J Med Chem; 2013 Oct; 68():312-20. PubMed ID: 23994324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].
    Biftu T; Qian X; Chen P; Feng D; Scapin G; Gao YD; Cox J; Roy RS; Eiermann G; He H; Lyons K; Salituro G; Patel S; Petrov A; Xu F; Xu SS; Zhang B; Caldwell C; Wu JK; Lyons K; Weber AE
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5361-6. PubMed ID: 23972441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
    Wallace MB; Feng J; Zhang Z; Skene RJ; Shi L; Caster CL; Kassel DB; Xu R; Gwaltney SL
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2362-7. PubMed ID: 18346892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
    Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.